Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report

Parvin Begum; Wanyuan Cui; Sanjay Popat

doi:10.1016/j.jtocrr.2022.100376

Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report

JTO Clin Res Rep. 2022 Jul 5;3(9):100376. doi: 10.1016/j.jtocrr.2022.100376. eCollection 2022 Sep.

Authors

Parvin Begum¹, Wanyuan Cui¹, Sanjay Popat^{1

2}

Affiliations

¹ Lung Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
² Institute of Cancer Research, London, United Kingdom.

Abstract

gene rearrangements occur in 1% to 2% of NSCLC. Acquired "on-target" mutations within the ROS1 kinase domain are a known resistance mechanism to the first-line ROS1 inhibitor crizotinib. Here, we report the first case of a patient with an acquired ROS1 G2101A resistance mutation after first-line crizotinib, who responded to lorlatinib. The response was dramatic but short in duration.

Keywords: Case report; Lorlatinib; Non–small cell lung cancer; ROS1 fusion; ctDNA.

Publication types

Case Reports